Clinical trials
Myasthenia Gravis Crisis clinical trials
Below are recruiting myasthenia gravis crisis clinical trials, each written for real people, not researchers. We’re tracking 18 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07761026Recruiting
Living with myasthenia gravis: share your experience
This 10-year study collects information from people with myasthenia gravis to learn more about the condition and improve care. By sharing your experiences, you can help researchers understand what daily life is like and shape future treatments.
Framingham, MassachusettsAges 18 years+ - NCT06860633RecruitingPhase 4
Efgartigimod for worsening myasthenia gravis in hospital
This trial tests a drug called efgartigimod for people with myasthenia gravis who are in the hospital because their symptoms are getting worse. The goal is to see if it can help them recover faster and avoid needing a breathing tube.
Aurora, ColoradoAges 18 years+ - NCT04837625Recruiting
Study of myasthenic crisis treatments for emergency breathing problems
This trial studies myasthenic crisis—an urgent, life-threatening worsening of myasthenia gravis that can affect breathing. It aims to better understand and treat people who need breathing support now, or may need it soon.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04951622RecruitingPhase 3
Testing nipocalimab for adults with generalized myasthenia gravis
This Phase 3 study tests nipocalimab, a medication given by infusion (and in some groups by injections under the skin), to improve symptoms in adults with generalized myasthenia gravis (MG). It may help reduce weakness in daily activities, especially if you meet specific symptom and safety criteria.
Paradise Valley, ArizonaAges 18 years+ - NCT05214612Recruiting
Predictors of outcomes in myasthenia gravis
This study looks at what helps predict outcomes in people with myasthenia gravis (MG). It may help doctors better forecast how MG will progress and which factors matter most for recovery and long-term health.
AsyutAges 16 years+ - NCT06371040RecruitingPhase 1
CAR-T cell therapy for severe myasthenia gravis
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
Xi'an, ShaanxiAges 18–80 - NCT06617741Recruiting
Global Registry for Myasthenia Gravis Patients
This trial is a global registry for people with myasthenia gravis (MG). It collects information to help researchers better understand MG and improve care.
Westborough, MassachusettsAges 18 years+ - NCT07146425Recruiting
Building a digital assessment model for myasthenia gravis
This study uses digital tools like questionnaires and smartphone tests to measure how myasthenia gravis affects you. It aims to create a better way for doctors to track your symptoms and adjust treatment.
ShanghaiAges 18 years+ - NCT07246564RecruitingPhase 4
Rozanolixizumab for Generalized Myasthenia Gravis in Chinese Adults
This study tests an investigational drug called rozanolixizumab for Chinese adults with generalized myasthenia gravis who have a specific antibody (AChR or MuSK) and symptoms that still affect daily activities. It aims to see if the drug helps improve muscle strength and quality of life.
BeijingAges 18 years+ - NCT07039916RecruitingPhase 3
Study of IMVT-1402 for mild to severe generalized myasthenia gravis
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
Huntsville, AlabamaAges 18–80 - NCT06704269RecruitingPhase 1/Phase 2
YTB323 for treatment-resistant generalized myasthenia gravis
This trial tests a new CAR-T cell therapy (YTB323) for people with generalized myasthenia gravis that hasn't been well-controlled by standard treatments. The goal is to see if it can safely improve symptoms and change how the immune system attacks the nerves.
Orange, CaliforniaAges 18–65 - NCT06463587RecruitingTeam says not enrollingPhase 3
Oral cladribine for generalized myasthenia gravis
This study tests a new oral medication (cladribine) to see if it can reduce muscle weakness and daily symptoms in people with generalized myasthenia gravis. It compares the drug to a placebo (a pill with no active medicine) to check safety and effectiveness.
Phoenix, ArizonaAges 18 years+ - NCT07411963Recruiting
Early ravulizumab for severe myasthenia gravis crisis in the ICU
This study tests whether starting ravulizumab early, after plasma exchange or IVIg, can help people with a severe myasthenia gravis crisis who are in the intensive care unit. It aims to see if it improves their condition.
Nice, Alpes-maritimesAges 18 years+ - NCT06866652Recruiting
Why Am I Short of Breath? A Study in Myasthenia Gravis
This study looks at why people with myasthenia gravis (MG) feel short of breath. It aims to understand breathing problems that happen in daily life, even when MG seems stable.
ParisAges 18 years+ - NCT07304154RecruitingPhase 1
Study of KITE-363 for autoimmune nerve diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Newport Beach, CaliforniaAges 18–75 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT07470151Recruiting
Study of EVM18001 for hard-to-treat autoimmune diseases
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Wuhan, HubeiAges 18–70 - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75
Hear when a new Myasthenia Gravis Crisis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myasthenia gravis crisis?
- Yes. Clin2 currently lists 18 recruiting myasthenia gravis crisis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myasthenia gravis crisis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myasthenia gravis crisis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.